Related Experiment Video
Updated: Sep 12, 2026

09:02
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Phase II trial of N-methylformamide in advanced renal cancer
1University of Maryland Cancer Center, Department of Internal Medicine, Baltimore 21201.
American Journal of Clinical Oncology
|February 1, 1989
Abstract:
N-methylformamide (NMF) (800-1,000 mg/m2 i.v. day 1) was given to 14 patients with measurable, advanced renal cell carcinoma in this Phase II trial. Treatment was repeated every 28 days. Significant toxicities included drug-induced hepatitis along with moderate nausea and vomiting. No objective responses were seen although several patients had stable disease with treatment for prolonged periods. NMF is not an active agent in renal cell cancer when administered by this schedule.

